192 related articles for article (PubMed ID: 27525651)
41. Early cellular immune response to a new candidate mycobacterial vaccine antigen in childhood tuberculosis.
Schepers K; Dirix V; Mouchet F; Verscheure V; Lecher S; Locht C; Mascart F
Vaccine; 2015 Feb; 33(8):1077-83. PubMed ID: 25583385
[TBL] [Abstract][Full Text] [Related]
42. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.
Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L
Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321
[TBL] [Abstract][Full Text] [Related]
43. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.
Billeskov R; Grandal MV; Poulsen C; Christensen JP; Winther N; Vingsbo-Lundberg C; Hoang TT; van Deurs B; Song YH; Aagaard C; Andersen P; Dietrich J
Eur J Immunol; 2010 May; 40(5):1342-54. PubMed ID: 20186878
[TBL] [Abstract][Full Text] [Related]
44. Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation.
Leal IS; Smedegård B; Andersen P; Appelberg R
Immunology; 2001 Oct; 104(2):157-61. PubMed ID: 11683955
[TBL] [Abstract][Full Text] [Related]
45. Protection against an aerogenic Mycobacterium tuberculosis infection in BCG-immunized and DNA-vaccinated mice is associated with early type I cytokine responses.
Goter-Robinson C; Derrick SC; Yang AL; Jeon BY; Morris SL
Vaccine; 2006 Apr; 24(17):3522-9. PubMed ID: 16519971
[TBL] [Abstract][Full Text] [Related]
46. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
[TBL] [Abstract][Full Text] [Related]
47. DNA vaccine with discontinuous T-cell epitope insertions into HSP65 scaffold as a potential means to improve immunogenicity of multi-epitope Mycobacterium tuberculosis vaccine.
Wu M; Li M; Yue Y; Xu W
Microbiol Immunol; 2016 Sep; 60(9):634-45. PubMed ID: 27531823
[TBL] [Abstract][Full Text] [Related]
48. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis.
Clark S; Cross ML; Smith A; Court P; Vipond J; Nadian A; Hewinson RG; Batchelor HK; Perrie Y; Williams A; Aldwell FE; Chambers MA
Vaccine; 2008 Oct; 26(46):5791-7. PubMed ID: 18789366
[TBL] [Abstract][Full Text] [Related]
49. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
Xing Z; Charters TJ
Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
[TBL] [Abstract][Full Text] [Related]
50. Boosting BCG to protect against TB.
Rouanet C; Locht C
Expert Rev Respir Med; 2010 Jun; 4(3):339-48. PubMed ID: 20524917
[TBL] [Abstract][Full Text] [Related]
51. Interferon-gamma production by mononuclear cells in Bacille Calmette-Guérin-revaccinated healthy volunteers predicted long-term antimycobacterial responses in a randomized controlled trial.
Oliveira ES; Marinho JM; Barbosa T;
Vaccine; 2013 Aug; 31(37):3778-82. PubMed ID: 23684832
[TBL] [Abstract][Full Text] [Related]
52. The present and future of tuberculosis vaccinations.
Principi N; Esposito S
Tuberculosis (Edinb); 2015 Jan; 95(1):6-13. PubMed ID: 25458613
[TBL] [Abstract][Full Text] [Related]
53. [Dimo-thylidioctyl ammonium bromide-BCG polysaccharide nucleic acid adjuvant enhanced the immunogenicity of a Mycobacterium tuberculosis subunit vaccine].
Song NN; Wang BX; Shi DZ; Fu LF; Luo Y; Yu HJ; Han SB; Jiao L; Qie YQ; Wang HH; Zhang Y; Zhu BD
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Jul; 32(7):513-6. PubMed ID: 19954005
[TBL] [Abstract][Full Text] [Related]
54. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice.
Stylianou E; Diogo GR; Pepponi I; van Dolleweerd C; Arias MA; Locht C; Rider CC; Sibley L; Cutting SM; Loxley A; Ma JK; Reljic R
Eur J Immunol; 2014 Feb; 44(2):440-9. PubMed ID: 24214530
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W
Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259
[TBL] [Abstract][Full Text] [Related]
56. Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.
Agger EM
Adv Drug Deliv Rev; 2016 Jul; 102():73-82. PubMed ID: 26596558
[TBL] [Abstract][Full Text] [Related]
57. Frequency of IFN-gamma producing cells correlates with adjuvant enhancement of bacille Calmette-Guèrin induced protection against Mycobacterium bovis.
Logan KE; Chambers MA; Hewinson RG; Hogarth PJ
Vaccine; 2005 Dec; 23(48-49):5526-32. PubMed ID: 16105710
[TBL] [Abstract][Full Text] [Related]
58. Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccination.
Clark SO; Kelly DL; Badell E; Castello-Branco LR; Aldwell F; Winter N; Lewis DJ; Marsh PD
Vaccine; 2010 Oct; 28(43):7109-16. PubMed ID: 20708695
[TBL] [Abstract][Full Text] [Related]
59. Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.
Siddiqui KF; Amir M; Khan N; Rama Krishna G; Sheikh JA; Rajagopal K; Agrewala JN
Clin Exp Immunol; 2015 Aug; 181(2):286-96. PubMed ID: 25845290
[TBL] [Abstract][Full Text] [Related]
60. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.
Hoft DF; Blazevic A; Abate G; Hanekom WA; Kaplan G; Soler JH; Weichold F; Geiter L; Sadoff JC; Horwitz MA
J Infect Dis; 2008 Nov; 198(10):1491-501. PubMed ID: 18808333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
